Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis
C Voskens, D Stoica, M Rosenberg, F Vitali, S Zundler… - Gut, 2023 - gut.bmj.com
C Voskens, D Stoica, M Rosenberg, F Vitali, S Zundler, M Ganslmayer, H Knott, M Wiesinger…
Gut, 2023•gut.bmj.comObjective Ulcerative colitis (UC) is a chronic, debilitating immune-mediated disease driven
by disturbed mucosal homeostasis, with an excess of intestinal effector T cells and an
insufficient expansion of mucosal regulatory T cells (Tregs). We here report on the
successful adoptive transfer of autologous, ex vivo expanded Tregs in a patient with
refractory UC and associated primary sclerosing cholangitis (PSC), for which effective
therapy is currently not available. Design The patient received a single infusion of 1× 106 …
by disturbed mucosal homeostasis, with an excess of intestinal effector T cells and an
insufficient expansion of mucosal regulatory T cells (Tregs). We here report on the
successful adoptive transfer of autologous, ex vivo expanded Tregs in a patient with
refractory UC and associated primary sclerosing cholangitis (PSC), for which effective
therapy is currently not available. Design The patient received a single infusion of 1× 106 …
Objective
Ulcerative colitis (UC) is a chronic, debilitating immune-mediated disease driven by disturbed mucosal homeostasis, with an excess of intestinal effector T cells and an insufficient expansion of mucosal regulatory T cells (Tregs). We here report on the successful adoptive transfer of autologous, ex vivo expanded Tregs in a patient with refractory UC and associated primary sclerosing cholangitis (PSC), for which effective therapy is currently not available.
Design
The patient received a single infusion of 1×106 autologous, ex vivo expanded, polyclonal Tregs per kilogram of body weight, and the clinical, biochemical, endoscopic and histological responses were assessed 4 and 12 weeks after adoptive Treg transfer.
Results
The patient showed clinical, biochemical, endoscopic and histological signs of response until week 12 after adoptive Treg transfer, which was associated with an enrichment of intestinal CD3+/FoxP3+ and CD3+/IL-10+ T cells and increased mucosal transforming growth factor beta and amphiregulin levels. Moreover, there was marked improvement of PSC with reduction of liver enzymes. This pronounced effect lasted for 4 weeks before values started to increase again.
Conclusion
These findings suggest that adoptive Treg therapy might be effective in refractory UC and might open new avenues for clinical trials in PSC.
Trial registration number
NCT04691232.
gut.bmj.com